ClinicalTrials.Veeva

Menu

REmote iSchemic Conditioning in acUtE BRAin INfarction Study (RESCUE-BRAIN)

V

Versailles Hospital

Status

Unknown

Conditions

Cerebral Infarction

Treatments

Device: Lower limb tourniquet
Other: Usual care

Study type

Interventional

Funder types

Other

Identifiers

NCT02189928
P14/01_RESCUE BRAIN
2014-A00104-43 (Registry Identifier)

Details and patient eligibility

About

Cerebral infarction is the most common form of stroke (80% of strokes). Stroke is the first cause of acquired disability, and the 2nd cause of dementia and death. The only approved treatment in the first 4.5 hour is intravenous rt-PA thrombolysis (Actilyse ®) whose objective is recanalization of occluded artery and reperfusion of the brain parenchyma. Few patients are treated (1-5%) and they keep disability in 50-60% of cases. This handicap is mainly correlated to the final infarct size. The objective of neuroprotective treatments is to reduce the final size of the cerebral infarction.

The per-conditioning remote ischemic (Per-CID) showed a neuroprotective effect in cerebral ischemia by reducing the final size of cerebral infarction animal models. The per-CID corresponds, in cases of cerebral ischemia, to iterative ischemia realization of a member with a cuff. In humans, the per-CID has shown a cardioprotective effect in a randomized control trial involving 250 patients within 6 first hours of myocardial infarction and candidate for primary angioplasty.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients ≥ 18 years
  • Carotid ischemic stroke
  • NIHSS score between 5 and 25
  • Brain MRI performed within 6 hours from symptoms onset
  • Obtaining a written informed consent of the patient or a third party (parent or close), or emergency inclusion process
  • Affiliated with a Medicare (or rightful beneficiary)

Exclusion criteria

  • Presence of a leg ulcer or a bad skin condition in the lower limbs
  • History of arterial occlusive disease of the lower limbs
  • Sickle cell disease known (risk of vaso-occlusive crisis)
  • History of phlebitis in the lower limbs
  • History of cerebral infarction older than 3 months
  • Participation in another interventional acute phase protocol
  • Patients under guardianship
  • Pathologies involving life-threatening within 6 months and making it impossible to evaluate to 3 months
  • Patient non-self before the ischemic stroke (Rankin Score previous> 2)
  • Pregnant Women

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

200 participants in 2 patient groups

With per-CID protocol
Experimental group
Description:
Usual care patients (thrombolysis or not ) with remote ischemic per-conditioning using an electronic tourniquet .
Treatment:
Device: Lower limb tourniquet
Without per-CID protocol
Other group
Description:
Usual care patients (thrombolysis or not).
Treatment:
Other: Usual care

Trial contacts and locations

9

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems